ADEMPAS STIMULATES THE
NO-sGC-cGMP PATHWAY REGARDLESS OF NO LEVEL1

PAH (WHO Group 1) and CTEPH (WHO Group 4) are associated with endothelial dysfunction, impaired synthesis of nitric oxide (NO), and insufficient stimulation of the NO-sGC-cGMP pathway. Adempas stimulates sGC, regardless of NO level, to produce more cGMP.1

cGMP=cyclic guanosine monophosphate; CTEPH=chronic thromboembolic pulmonary hypertension; PAH=pulmonary arterial hypertension; sGC=soluble guanylate cyclase; WHO=World Health Organization

phone

Want clinical updates and helpful resources?

Request a Bayer sales representative here.

MORE IMPORTANT SAFETY INFORMATION LESS IMPORTANT SAFETY INFORMATION
References:
  1. Adempas Prescribing Information. Whippany, NJ. Bayer Pharmaceuticals Inc., 2018.

How Adempas Works